Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Chae, Yee Soo | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Nam, Byung-Ho | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Ro, Jungsil | - |
dc.date.accessioned | 2021-08-31T20:44:04Z | - |
dc.date.available | 2021-08-31T20:44:04Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-12-10 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/60934 | - |
dc.description.abstract | BACKGROUND: The continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments. METHODS: A total of 149 patients were randomly assigned to lapatinib with vinorelbine (LV) (n = 75; lapatinib, 1000 mg daily; vinorelbine 20 mg/m(2) D1, D8 q3w) or vinorelbine (V) (n = 74; 30 mg/m(2) D1, D8 q3w). The primary endpoint was progression-free survival (PFS) rate at 18 weeks. RESULTS: The median number of previous anti-HER2 therapies was 2 (range 2-5). There was no significant difference in PFS rate at 18 weeks between LV and V arms (45.9% vs 38.9%, p = 0.40). ORR was 19.7% in LV arm, and 16.9% in V arm (p = 0.88). PFS and OS did not differ between two arms (LV vs V; median PFS, 16 vs 12 weeks, HR = 0.86, 95% CI 0.61-1.22; median OS, 15.0 vs 18.9 months, HR = 1.07, 95% CI 0.72-1.58). Toxicity profiles were similar in both arms and all were manageable. CONCLUSIONS: Lapatinib plus vinorelbine treatment was tolerable; however, it failed to demonstrate the clinical benefits over vinorelbine alone in patients with HER2 + MBC after progression on both trastuzumab and lapatinib. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | GROWTH-FACTOR RECEPTOR | - |
dc.subject | PLUS CAPECITABINE | - |
dc.subject | PROGRESSION | - |
dc.subject | RESISTANCE | - |
dc.subject | EMTANSINE | - |
dc.title | Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, In Hae | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.identifier.doi | 10.1038/s41416-019-0618-z | - |
dc.identifier.scopusid | 2-s2.0-85074795875 | - |
dc.identifier.wosid | 000502070600001 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, v.121, no.12, pp.985 - 990 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.citation.title | BRITISH JOURNAL OF CANCER | - |
dc.citation.volume | 121 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 985 | - |
dc.citation.endPage | 990 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | PLUS CAPECITABINE | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EMTANSINE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.